FY2025 EPS Estimates for Lantheus Lowered by Leerink Partnrs

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Research analysts at Leerink Partnrs cut their FY2025 earnings estimates for shares of Lantheus in a note issued to investors on Wednesday, November 12th. Leerink Partnrs analyst R. Ruiz now expects that the medical equipment provider will post earnings per share of $4.55 for the year, down from their prior estimate of $4.84. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. Leerink Partnrs also issued estimates for Lantheus’ Q4 2025 earnings at $0.89 EPS and FY2026 earnings at $4.88 EPS.

Other research analysts have also recently issued reports about the stock. B. Riley cut their price target on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, September 16th. The Goldman Sachs Group set a $77.00 target price on shares of Lantheus and gave the stock a “neutral” rating in a research report on Wednesday, October 8th. Mizuho decreased their price target on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. Weiss Ratings cut Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Finally, Truist Financial restated a “hold” rating and set a $61.00 price objective (down from $63.00) on shares of Lantheus in a report on Monday, November 10th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Lantheus presently has a consensus rating of “Hold” and a consensus price target of $74.17.

Lantheus Stock Down 0.2%

Shares of NASDAQ LNTH opened at $53.01 on Monday. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07. The company has a market cap of $3.52 billion, a P/E ratio of 14.10 and a beta of 0.04. Lantheus has a 1 year low of $47.25 and a 1 year high of $111.29. The firm has a 50-day simple moving average of $53.90 and a two-hundred day simple moving average of $66.50.

Lantheus (NASDAQ:LNTH) last released its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. The firm had revenue of $92.51 million for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Elevation Point Wealth Partners LLC acquired a new stake in shares of Lantheus during the second quarter worth $26,000. Signaturefd LLC raised its stake in Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 116 shares during the last quarter. Osterweis Capital Management Inc. acquired a new stake in Lantheus during the 2nd quarter worth about $36,000. Quarry LP grew its stake in Lantheus by 2,350.0% during the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 470 shares during the last quarter. Finally, Hantz Financial Services Inc. increased its holdings in shares of Lantheus by 412.5% in the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 396 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Buying and Selling at Lantheus

In related news, insider Rajiv A. Patel sold 3,365,000 shares of the business’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the business’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 6,812,000 shares of company stock valued at $382,427,380. Company insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.